Topic summary

Tesamorelin has an approved indication — what that changes about the evidence

Compounds › Secretagogues & GH axis observational data tesamorelin GHRP class CJC-1295 ipamorelin

This is a generated summary. It shows the 5 most-liked posts from a topic of 28, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.

p.mwangiTL2 Moderator17 Apr 2026#2

This follows the opening post rather than contradicting it.

Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the kind that comes from remembering a figure instead of looking it up.

23 likes 3mo

j.fonsecaTL2 Moderator8 May 2026#6

Pulsatile secretion matters because growth hormone is secreted in pulses, not continuously. A single post-dose growth hormone level is nearly uninterpretable. Assessing this class properly requires serial sampling or an integrated measure like IGF-1, and almost nothing published online does either.

30 likes 3mo

ZieglerTL3Regular2 Jun 2026#12

I read post #10 twice before replying, because I had assumed the opposite.

Tesamorelin has an approved indication in HIV-associated lipodystrophy. That is the only compound in this class with a registration-quality evidence base from a proper trial programme. Generalising from that narrow population to healthy adults is a substantial extrapolation.

22 likes 2mo

v.fontaineTL2 Moderator17 Jul 2026#25

Coming back to post #23, because the follow-up matters more than the original answer.

31 likes 11d

s.rasmussenTL2 Moderator27 Jul 2026 · edited#28

23 likes 1d

Read the full topic (28 posts)

This topic was referenced in

Reading a rodent study on a secretagogue without over-extrapolatingCompounds › Secretagogues & GH axis · 54 replies
Second pass at: Why this subcategory is stricter about sourcing than mostCompounds › Secretagogues & GH axis · 129 replies

Promoted into the documentation commons. The content of this topic is maintained at CJC-1295 — reference, with named maintainers and a review date. The promotion was discussed in doc review. Corrections are best raised against the document, which is the version that gets kept current.

Suggested topics

Topic	Participants	Replies	Views	Activity
Reading a rodent study on a secretagogue without over-extrapolating Compounds › Secretagogues & GH axis observational data GHRP class CJC-1295 needs a source Closed Posting this under the heading it deserves: Reading a rodent study on a secretagogue without over-extrapolating Everything below is what sits behind that. I have seen STEP 8 ( JAMA , 2022) cited in support of…	+50	54	32k	10mo
Ipamorelin selectivity claims and where they came from — a second dataset Compounds › Secretagogues & GH axis CJC-1295 GHRP class tesamorelin ipamorelin Posting this under the heading it deserves: Ipamorelin selectivity claims and where they came from — a second dataset Everything below is what sits behind that. I have seen SURPASS-2 ( N Engl J Med , 2021)…		2	27k	14mo
Secretagogues and glucose tolerance: the mechanistic concern — what changed since Compounds › Secretagogues & GH axis GHRP class ipamorelin CJC-1295 observational data Wiki Closed Secretagogues and glucose tolerance: the mechanistic concern — what changed since Writing it up because I had to work it out twice and would rather nobody else did. I have seen STEP 1 ( N Engl J Med , 2021)…	+2	6	31k	2mo
GHRH analogues versus ghrelin mimetics: different mechanisms, conflated discussion Compounds › Secretagogues & GH axis CJC-1295 observational data ipamorelin needs a source Solved On the subject in the title: GHRH analogues versus ghrelin mimetics: different mechanisms, conflated discussion Working notes rather than a conclusion. I have seen STEP 2 ( Lancet , 2021) cited in support of…	+47	53	6.9k	2h
IGF-1 as a surrogate endpoint and its limitations — the long version Compounds › Secretagogues & GH axis CJC-1295 observational data ipamorelin needs a source Solved Closed On the subject in the title: IGF-1 as a surrogate endpoint and its limitations — the long version Working notes rather than a conclusion. I have seen STEP 2 ( Lancet , 2021) cited in support of a claim I do…	+14	18	53k	12mo

Related topics — sharing the tags observational data, tesamorelin, GHRP class

Topic	Participants	Replies	Views	Activity
Publication patterns in the BPC-157 literature, examined Compounds › Repair & healing peptides preprint BPC-157 TB-500 needs a source Solved Posting this under the heading it deserves: Publication patterns in the BPC-157 literature, examined Everything below is what sits behind that. I have seen SURPASS-2 ( N Engl J Med , 2021) cited in support of…	+40	45	3.4k	21h
Whether an aggregate is worth publishing at all: a disputed topic — does this still hold? Data & Tools › Datasets data table confounding observational data Solved Whether an aggregate is worth publishing at all: a disputed topic — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below. I would like to understand…	+14	18	3.4k	2mo
Coming back to: A community side-effect dataset, with its response rate and biases Data & Tools › Datasets observational data site feedback confounding data table On the subject in the title: A community side-effect dataset, with its response rate and biases Working notes rather than a conclusion. Posting the method first, because I know what the first three replies…	+27	31	46k	9mo
CJC-1295 with and without DAC: what the modification does Compounds › Secretagogues & GH axis needs a source tesamorelin CJC-1295 GHRP class On the subject in the title: CJC-1295 with and without DAC: what the modification does Working notes rather than a conclusion. Comparing PIONEER 6 ( N Engl J Med , 2019) with SURMOUNT-OSA ( N Engl J Med ,…	+117	123	5.6k	22h
A critique that turned out to be unfair, retracted by its author Evidence › Study critique confounding risk of bias effect size observational data Wiki Posting this under the heading it deserves: A critique that turned out to be unfair, retracted by its author Everything below is what sits behind that. Session topic: SURMOUNT-4 ( JAMA , 2024). Please read it…	+34	38	20k	17h